Cabozantinib: all 199 studies that test it
Page 2 of 2. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.
- Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT01716715Phase 2Results posted
- Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid TumorsCompletedNCT01709435Phase 1Results posted
- Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT01708954Phase 2Results posted
- Cabozantinib in Men With Castration-Resistant Prostate CancerTerminatedNCT01703065Phase 2Results posted
- Cabozantinib for Advanced Urothelial CancerCompletedNCT01688999Phase 2Results posted
- Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate CancerCompletedNCT01683994Phase 1/2Results posted
- A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic CancerCompletedNCT01663272Phase 1Results posted
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results posted
- Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate CancerCompletedNCT01630590Phase 2Results posted
- Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100CompletedNCT01605227Phase 3Results posted
- Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate CancerCompletedNCT01599793Phase 2Results posted
- Cabozantinib in Advanced Solid MalignanciesCompletedNCT01588821Phase 2Results posted
- Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerTerminatedNCT01522443Phase 3Results posted
- Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid TumorsCompletedNCT01466036Phase 2Results posted
- Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to BoneTerminatedNCT01428219Phase 2Results posted
- Cabozantinib (XL184) in Men With Castrate-Resistant Prostate CancerCompletedNCT01347788Phase 1Results posted
- Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseTerminatedNCT01068782Phase 2Results posted
- Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesCompletedNCT00940225Phase 2Results posted
- Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid CancerCompletedNCT00704730Phase 3Results posted
- Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeCompletedNCT00704288Phase 2Results posted
- A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell CarcinomaTerminatedNCT06716853Phase 1/2
- Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells CancerTerminatedNCT06377722Phase 2
- Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With OsteosarcomaTerminatedNCT06341712Phase 2
- caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.Active, not recruitingNCT06171854Phase 2
- A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the BrainActive, not recruitingNCT06132945Phase 1
- Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaActive, not recruitingNCT05836571Phase 2
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed OsteosarcomaSuspendedNCT05691478Phase 2/3
- Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCSuspendedNCT05663710Phase 1/2
- Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.CompletedNCT05660954Phase 2
- Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT05502315Phase 2
- Multiparametric Assessment of Bone Response in mCRPC Patients Treated With CabozantinibCompletedNCT05265988Phase 2
- Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine TumorsActive, not recruitingNCT05249114Phase 1
- Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
- A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyWithdrawnNCT05039736Phase 2
- Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid TumorsCompletedNCT05038839Phase 1
- Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT05007613Phase 2
- Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerActive, not recruitingNCT04963283Phase 2
- A Phase II Trial of Cabozantinib With Patients With Refractory GCTsCompletedNCT04876456Phase 2
- Study of Cabozantinib Plus TAS102 in mCRC as Salvage TherapyCompletedNCT04868773Phase 1
- Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 InhibitorsCompletedNCT04767906Phase 2
- Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell CarcinomaStatus unknownNCT04714697Phase 2
- Cabozantinib With Topotecan-CyclophosphamideCompletedNCT04661852Phase 1
- Cabozantinib in Hepatocellular CarcinomaActive, not recruitingNCT04588051Phase 2
- A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3Active, not recruitingNCT04524208Phase 2
- Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver FunctionCompletedNCT04522908Phase 2
- Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line TreatmentCompletedNCT04511455Phase 2
- Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)CompletedNCT04477512Phase 1
- A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver FunctionStatus unknownNCT04454762Phase 2
- Efficacy and Safety of Cabozantinib in Patients With Hepatocellular CarcinomaStatus unknownNCT04435977Phase 2
- A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETStatus unknownNCT04427787Phase 2
- Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCActive, not recruitingNCT04413123Phase 2
- Cabozantinib in High Grade Neuroendocrine NeoplasmsActive, not recruitingNCT04412629Phase 2
- CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase InhibitionActive, not recruitingNCT04322955Phase 2
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04310007Phase 2
- Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT04300140Phase 1/2
- Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr CancerActive, not recruitingNCT04289779Phase 2
- Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerTerminatedNCT04230954Phase 2
- Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant MesotheliomaTerminatedNCT04173338Phase 1
- Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaWithdrawnNCT04149275Phase 2
- Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR StudyCompletedNCT04134390Phase 2
- Phase II Study With Cabozantinib in Patients With RET Positive NSCLCStatus unknownNCT04131543Phase 2
- Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.TerminatedNCT04066595Phase 2
- Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain MetastasesCompletedNCT03967522Phase 2
- Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)CompletedNCT03963206Phase 4
- Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)Status unknownNCT03943602Phase 2
- CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET DeregulationStatus unknownNCT03911193Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"Status unknownNCT03824691Phase 2
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingNCT03793166Phase 3
- Cabozantinib in Advanced Salivary Gland Cancer PatientsTerminatedNCT03729297Phase 2
- ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)CompletedNCT03685448Phase 2
- Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CancerCompletedNCT03667482Phase 1
- A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT03635892Phase 2
- A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)Active, not recruitingNCT03634540Phase 2
- Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid TumorsCompletedNCT03611595Phase 1
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaActive, not recruitingNCT03541902Phase 2
- A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinomaCompletedNCT03463681Phase 2
- Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)CompletedNCT03425201Phase 1/2
- caBozantinib in cOllectiNg ductS Renal Cell cArcInomaCompletedNCT03354884Phase 2
- Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)CompletedNCT03299946Phase 1
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
- Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT03200587Phase 1
- Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
- Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine CancerCompletedNCT02592356Not applicable
- Ph II CABOGIST in GISTCompletedNCT02216578Phase 2
- A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line SettingStatus unknownNCT02041260Phase 2
- IRCI Gynae Sarcomas, High Grade Uterine SarcomaCompletedNCT01979393Phase 2
- Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01961765Phase 1
- Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By SurgeryTerminatedNCT01835184Phase 1
- A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal FunctionCompletedNCT01761773Phase 1
- XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone DiseaseCompletedNCT01582295Phase 1
- XL-184+Abiraterone in Post-Chemo CRPCCompletedNCT01574937Phase 1
- Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced CancerCompletedNCT01553656Phase 1
- Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult SubjectsCompletedNCT01493869Phase 1
- A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid TumorsCompletedNCT01100619Phase 1
- Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in JapanCompletedNCT01018745Phase 1
- Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With GlioblastomaCompletedNCT00960492Phase 1
- Study of XL184 (Cabozantinib) in Adults With Advanced MalignanciesCompletedNCT00215605Phase 1